Mvtpharma
1 known investors
MVT develops patented microbubble and nanobubble formulations used as ultrasound contrast agents and for ultrasound-mediated therapies, with a lead product (MVT-100) for echocardiography that has completed Phase II trials. Its pipeline spans diagnostic imaging and treatment applications including brain, pancreatic and breast cancer, sonothrombolysis, and Alzheimer's disease.
BiotechHealthtechMedical Devices